Literature DB >> 30065096

Regulatory T Cells in Ovarian Cancer Are Characterized by a Highly Activated Phenotype Distinct from that in Melanoma.

Aras Toker1, Linh T Nguyen1, Simone C Stone1, S Y Cindy Yang2, Sarah Rachel Katz3, Patricia A Shaw4, Blaise A Clarke4, Danny Ghazarian4, Ayman Al-Habeeb4, Alexandra Easson5, Wey L Leong5, David R McCready5, Michael Reedijk1,2,5, Cynthia J Guidos6,7, Trevor J Pugh2,8, Marcus Q Bernardini3, Pamela S Ohashi9,2,6.   

Abstract

Purpose: Regulatory T (Treg) cells expressing the transcription factor FOXP3 are essential for the maintenance of immunologic self-tolerance but play a detrimental role in most cancers due to their ability to suppress antitumor immunity. The phenotype of human circulating Treg cells has been extensively studied, but less is known about tumor-infiltrating Treg cells. We studied the phenotype and function of tumor-infiltrating Treg cells in ovarian cancer and melanoma to identify potential Treg cell-associated molecules that can be targeted by tumor immunotherapies.Experimental Design: The phenotype of intratumoral and circulating Treg cells was analyzed by multicolor flow cytometry, mass cytometry, RNA-seq, and functional assays.
Results: Treg cells isolated from ovarian tumors displayed a distinct cell surface phenotype with increased expression of a number of receptors associated with TCR engagement, including PD-1, 4-1BB, and ICOS. Higher PD-1 and 4-1BB expression was associated with increased responsiveness to further TCR stimulation and increased suppressive capacity, respectively. Transcriptomic and mass cytometry analyses revealed the presence of Treg cell subpopulations and further supported a highly activated state specifically in ovarian tumors. In comparison, Treg cells infiltrating melanomas displayed lower FOXP3, PD-1, 4-1BB, and ICOS expression and were less potent suppressors of CD8 T-cell proliferation.Conclusions: The highly activated phenotype of ovarian tumor-infiltrating Treg cells may be a key component of an immunosuppressive tumor microenvironment. Receptors that are expressed by tumor-infiltrating Treg cells could be exploited for the design of novel combination tumor immunotherapies. Clin Cancer Res; 24(22); 5685-96. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30065096     DOI: 10.1158/1078-0432.CCR-18-0554

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  24 in total

1.  A Novel Pyroptosis-Related Gene Signature for Early-Stage Lung Squamous Cell Carcinoma.

Authors:  Xiaoyan Li; Jie He
Journal:  Int J Gen Med       Date:  2021-10-05

2.  Effects of PD-1 blockade on ovarian follicles in a prepubertal female mouse.

Authors:  Pauline C Xu; Yi Luan; Seok-Yeong Yu; Jing Xu; Donald W Coulter; So-Youn Kim
Journal:  J Endocrinol       Date:  2021-11-24       Impact factor: 4.286

3.  Extent and characteristics of immune infiltration in clear cell renal cell carcinoma and the prognostic value.

Authors:  Yuhao Wang; Jie Yang; Qijie Zhang; Jiadong Xia; Zengjun Wang
Journal:  Transl Androl Urol       Date:  2019-12

Review 4.  Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights.

Authors:  Sandeep Kumar; Sunil Kumar Singh; Basabi Rana; Ajay Rana
Journal:  Drug Discov Today       Date:  2021-01-12       Impact factor: 8.369

5.  Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer.

Authors:  Christopher A Chuckran; Anthony R Cillo; Jessica Moskovitz; Abigail Overacre-Delgoffe; Ashwin S Somasundaram; Feng Shan; Grant C Magnon; Sheryl R Kunning; Irina Abecassis; Amer H Zureikat; James Luketich; Arjun Pennathur; John Sembrat; Mauricio Rojas; Daniel T Merrick; Sarah E Taylor; Brian Orr; Francesmary Modugno; Ron Buckanovich; Robert E Schoen; Seungwon Kim; Umamaheswar Duvvuri; Herbert Zeh; Robert Edwards; John M Kirkwood; Lan Coffman; Robert L Ferris; Tullia C Bruno; Dario A A Vignali
Journal:  Sci Transl Med       Date:  2021-12-08       Impact factor: 19.319

Review 6.  The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors.

Authors:  Denisa Baci; Annalisa Bosi; Matteo Gallazzi; Manuela Rizzi; Douglas M Noonan; Alessandro Poggi; Antonino Bruno; Lorenzo Mortara
Journal:  Int J Mol Sci       Date:  2020-04-28       Impact factor: 5.923

7.  CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer.

Authors:  Christina Friese; Katja Harbst; Troels Holz Borch; Marie Christine Wulff Westergaard; Magnus Pedersen; Anders Kverneland; Göran Jönsson; Marco Donia; Inge Marie Svane; Özcan Met
Journal:  Sci Rep       Date:  2020-03-03       Impact factor: 4.379

8.  GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study.

Authors:  Premal H Thaker; William H Bradley; Charles A Leath; Camille Gunderson Jackson; Nicholas Borys; Khursheed Anwer; Lauren Musso; Junko Matsuzaki; Wiam Bshara; Kunle Odunsi; Ronald D Alvarez
Journal:  Clin Cancer Res       Date:  2021-07-29       Impact factor: 13.801

Review 9.  Turning the Tide Against Regulatory T Cells.

Authors:  SeongJun Han; Aras Toker; Zhe Qi Liu; Pamela S Ohashi
Journal:  Front Oncol       Date:  2019-04-16       Impact factor: 6.244

10.  Human Tregs at the materno-fetal interface show site-specific adaptation reminiscent of tumor Tregs.

Authors:  Judith Wienke; Laura Brouwers; Leone M van der Burg; Michal Mokry; Rianne C Scholman; Peter Gj Nikkels; Bas B van Rijn; Femke van Wijk
Journal:  JCI Insight       Date:  2020-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.